

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/500,964
Filing Date	July 8, 2004
First Named Inventor	Sugasawa, Keizo
Art Unit	1625
Examiner Name	Chang, Cecelia C.
Attorney Docket Number	401.1013US

Sheet 3 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	KIMURA, TATSUYA, et al., "A non-peptide compound which can mimic the effect of thrombopoietin via e-mp1", FEBS Letters. 428,1998, 250-254	
	CB	International Search Report for WO 2005/007651, corresponding to U.S. Appln. serial no. 10/564,520.	
	CC	International Preliminary Report on Patentability from International Application no. PCT/IB2006/003142 (corresponding to US 11/593,758).	
	CD	KUTER, et al., "Recombinant Human Thrombopoietin: Basic Biology and Evaluation of Clinical Studies, Blood 2002, vol. 100, no. 10	
	CE	VADHAN-RAJ, et al., "Recom. Hum. Thrombopoietin Attenuates Carboplatin-Indcd. Svre. Thrombocytopenia", Annals of Internal Medicine 2002, vol. 132, no. 5, pp 364-368	
	CF	VADHAN-RAJ, et al., "Import. of Predosing of Recomb. Hum. Thrombopoietin to Rdce. Chemotherapy-Indcd. Erly.", Journal of Clinical Oncology 2003, Vol 21, No. 16, pp 3158-3167	
	CG	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects", 1005, CRC Press, pp 6-8	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.